Athira biopharma: Mark Worthington joins as General Counsel
Athira Biopharma has appointed Mark Worthington (pictured) as General Counsel, effective June 1.
Worthington is Athira’s first general counsel as a public company. Christina Thomson, who was previously general counsel, left the company in July 2020 to join Sierra Oncology.
Mark Worthington profile
Prior to joining Athira, Worthington was a partner at Summit Law Group for 24 years, where he served in various management capacities. He has experience in corporate and securities law, serving . He has is also experienced in mergers and acquisitions in addition to a wide range of corporate finance transactions, including angel, venture capital and private equity financings as well as initial, secondary and follow-on public offerings. Worthington also advised private and public companies with respect to corporate governance and compliance issues such as federal and state securities laws, the JOBS Act, and ongoing SEC and other regulatory compliance and reporting.
Athira is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration.